Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
L. Hruby, K. Scharov, A. Delaidelli, D. Picard, C. Dunham, O. Lewandowska, T. Reiff, M. Larcher, C. Pouponnot, P. H. Sorensen, B. Rotblat, G. Reifenberger, M. Remke, G. Leprivier
This study shows that EIF4EBP1 is upregulated by MYC in medulloblastoma and linked to poorer patient survival.
bioRxiv · Mar 6, 2024 · PreprintCancer Biology
J. K. Lim, F. Stoelting, D. Roth, C. Ballmeyer, S. Tishina, L. Thewes, S. Kalis, S. Boussettaoui, D. Picard, H.-F. Zhang, O. Lewandowska, T. Reiff, T. Levy, B. Rotblat, M. Remke, , G. Leprivier
This study shows oncogenic RAS signaling suppresses ferroptosis by upregulating GCH1 and BH4, making RAS-driven cancers resistant to ferroptosis-inducing agents.
bioRxiv · Jan 27, 2024 · PreprintCancer Biology
A. K. Weiner, A. B. Radaoui, M. Tsang, D. Martinez, S. Sidoli, K. L. Conkrite, A. Delaidelli, A. Modi, J. L. Rokita, K. Patel, M. V. Lane, B. Zhang, C. Zhong, B. Ennis, D. P. Miller, , S. J. Diskin
This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.
bioRxiv · Dec 6, 2023 · PreprintCancer Biology
S. A. Yamada-Hunter, J. Theruvath, B. J. McIntosh, K. A. Freitas, M. T. Radosevich, A. Leruste, S. Dhingra, N. Martinez-Velez, P. Xu, A. Delaidelli, M. H. Desai, Z. Good, L. Labanieh, C. W. Mount, Y. Chen, , C. L. Mackall
This paper engineers a CD47 variant to protect T cells from macrophage clearance, enhancing antitumor efficacy by combining T cell and macrophage activation.
bioRxiv · Jun 20, 2023 · PreprintBioengineering
L. Ramos, S. Truong, B. Zhai, J. Joshi, F. Ghaidi, M. M. Lizardo, T. Shyp, H. Adomat, S. LeBihan, C. C. Collins, J. Bacha, D. Brown, J. Langlands, W. Shen, N. Lallous, , M. Daugaard
This paper develops a dual PARP and HDAC inhibitor, kt-3283, showing enhanced cytotoxicity and efficacy in Ewing sarcoma models compared to single-agent inhibitors.
bioRxiv · Nov 10, 2022 · PreprintCancer Biology
S. Lefort, A. El-Naggar, S. Tan, S. Colborne, G. L. Negri, D. Pellacani, M. Hirst, B. Gusterson, G. B. Morin, P. H. Sorensen, C. J. Eaves
This study shows YB-1 is essential for human breast cancer growth and metastasis, as its knockdown inhibits tumor formation and lung colonization in mice.
bioRxiv · Nov 20, 2020 · PreprintCancer Biology
A. Sipol, E. Hameister, B. Xue, A. Petry, C. Prexler, M. Barenboim, R. A. Rubio, M. C. Baldauf, D. G. Franchina, J. Schmaeh, G. Richter, G. Cario, T. G. P. Gruenewald, A. Goerlach, D. Brenner, , S. E. G. Burdach
This study shows MondoA promotes malignancy in pediatric cALL by enhancing metabolic stress adaptation, with potential therapeutic implications.
bioRxiv · Nov 1, 2020Cancer Biology
V. Evdokimova, P. Ruzanov, H. Gassmann, H. H. Zaidi, V. Peltekova, L. E. Heisler, J. D. McPherson, M. Orlic-Milacic, K. Specht, K. Steiger, S. J. Schober, U. Thiel, T. D. McKee, M. Zaidi, C. M. Spring, , P. H. Sorensen
This study identifies retroelement RNAs in Ewing Sarcoma exosomes that induce inflammation and immunosuppression in recipient cells.
bioRxiv · Oct 16, 2019 · PreprintCancer Biology